Table 3.
Univariable and multivariable Cox regression model in metastatic breast cancer (training cohort)
| Characteristic | Univariable hazard ratios | 95% CI | p-value | Multivariable hazard ratios | 95% CI | p-value |
|---|---|---|---|---|---|---|
| Age (yr) | 0.001 | 0.005 | ||||
| < 35 | 1 | 1 | ||||
| 35-50 | 0.500 | 0.334-0.749 | 0.001 | 0.526 | 0.306-0.906 | 0.020 |
| > 50 | 0.607 | 0.277-1.328 | 0.231 | 0.873 | 0.214-1.452 | 0.374 |
| Menopause status | ||||||
| Menopause vs. menses | 0.102 | 0.010-1.015 | 0.052 | |||
| Tumour size (cm) | 0.480 | |||||
| ≤ 2 | 1 | |||||
| > 2 and ≤ 5 | 1.266 | 0.802-1.998 | 0.312 | |||
| > 5 | 1.214 | 0.583-2.525 | 0.604 | |||
| Lymph node involvement | ||||||
| Yes vs. no | 1.382 | 0.577-3.310 | 0.468 | |||
| MFI | 0.006 | 0.007 | ||||
| Primary stage IV | 1 | 1 | ||||
| < 6 mo | 0.872 | 0.512-1.484 | 0.613 | 0.670 | 0.372-1.209 | 0.184 |
| 6 mo-2 yr | 1.257 | 0.752-2.103 | 0.383 | 0.780 | 0.369-1.648 | 0.515 |
| 2-5 yr | 0.773 | 0.371-1.612 | 0.492 | 0.469 | 0.157-1.402 | 0.176 |
| > 5 yr | 0.468 | 0.170-1.288 | 0.142 | 0.208 | 0.048-0.905 | 0.036 |
| No. of metastases | ||||||
| > 1 vs. 1 | 0.596 | 0.142-2.502 | 0.480 | |||
| Metastasis site | 0.001 | < 0.001 | ||||
| Visceral/CNS | 1 | 1 | ||||
| Bone/Soft tissue | 0.483 | 0.324-0.721 | < 0.001 | 0.745 | 0.478-1.163 | 0.195 |
| Multiple | 0.477 | 0.111-2.054 | 0.320 | 1.991 | 0.715-5.544 | 0.187 |
| HR status | ||||||
| HR+ vs. HR- | 0.321 | 0.131-0.788 | 0.013 | 0.270 | 0.102-0.711 | 0.008 |
| HER2 receptor status | 0.937 | |||||
| Non-amplification | 1 | |||||
| Amplification | 0.838 | 0.320-2.191 | 0.718 | |||
| Not known or equivocal (2+) | 0.702 | 0.090-5.456 | 0.735 |
CI, confidence interval; MFI, metastasis-free interval; CNS, central nervous system; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.